TABLE 1.
Clinical and pathological characteristics of 2511 men who underwent radical prostatectomy between 1983 and 2000 with available preoperative erectile dysfunction status
| ED group | No ED group | Total | P | |
|---|---|---|---|---|
| Number (%) | 231 (9.2) | 2280 (90.8) | 2511 (100) | |
| Age (years) | < 0.001 | |||
| <40 | 0 (0) | 24 (1) | 24 (0.9) | |
| 41–50 | 3 (1.3) | 345 (15.1) | 348 (13.9) | |
| 51–60 | 58 (25.1) | 1107 (48.6) | 1165 (46.4) | |
| 61–70 | 161 (69.7) | 788 (34.6) | 949 (37.8) | |
| >70 | 9 (3.9) | 16 (0.7) | 25 (1.0) | |
| BMI (kg/m2) | 0.31 | |||
| <25 | 66 (32.0) | 800 (37.8) | 866 (37.3) | |
| 25–30 | 115 (55.8) | 1131 (53.4) | 1246 (53.6) | |
| >30 | 25 (12.1) | 186 (8.8) | 211 (9.1) | |
| RRP year | <0.001 | |||
| 1983–1990 | 114 (49.3) | 786 (34.5) | 900 (35.8) | |
| 1991–2004 | 117 (50.7) | 1495 (65.5) | 1615 (64.2) | |
| PSA (ng/mL) | 0.46 | |||
| 0–2.6 | 23 (11.7) | 318 (15.7) | 341 (15.2) | |
| 2.6–4 | 26 (13.2) | 240 (11.8) | 266 (11.9) | |
| 4–10 | 97 (49.2) | 1037 (50.8) | 1134 (50.7) | |
| 10–20 | 40 (20.3) | 348 (17.0) | 388 (17.3) | |
| >20 | 11 (5.6) | 99 (4.9) | 110 (4.9) | |
| TNM stage | <0.001 | |||
| T1a/b | 30 (13.0) | 137 (6.0) | 167 (6.7) | |
| T1c | 65 (28.1) | 886 (38.9) | 951 (37.9) | |
| T2 | 132 (57.1) | 1204 (52.9) | 1336 (53.3) | |
| T3 | 4 (1.7) | 50 (2.2) | 54 (2.2) | |
| Biopsy Gleason score | 0.22 | |||
| 2–6 | 170 (75.2) | 1804 (80.4) | 1974 (79.9) | |
| 7 | 47 (20.8) | 366 (16.3) | 413 (16.7) | |
| 8–10 | 9 (3.9) | 75 (3.3) | 84 (3.4) | |
| Race | 0.56 | |||
| Caucasian | 223 (96.6) | 2158 (94.7) | 2381 (94.8) | |
| African American | 4 (1.7) | 59 (2.6) | 63 (2.5) | |
| Asian | 0 (0) | 6 (0.3) | 6 (0.2) | |
| Others | 3 (1.3) | 53 (2.3) | 56 (2.2) | |
| Pathologic stage | <0.001 | |||
| pT2 (OC) | 98 (42.4) | 1189 (52.3) | 1287 (51.4) | |
| pT3a (EPE) | 94 (40.7) | 844 (37.2) | 938 (37.5) | |
| pT3b (SVI) | 21 (9.1) | 105 (4.6) | 126 (5.0) | |
| LN+ | 18 (7.8) | 134 (5.9) | 152 (6.1) | |
| Gleason score from RRP | 0.24 | |||
| 2–6 | 133 (57.6) | 1418 (62.5) | 1551 (62.0) | |
| 7 | 76 (32.9) | 692 (30.5) | 768 (30.7) | |
| 8–10 | 22 (9.5) | 160 (7.1) | 182 (7.3) | |
| Charlson comorbidity index | 0.03 | |||
| 0 | 185 (81.5) | 1977 (87.5) | 2162 (86.9) | |
| 1 | 33 (14.5) | 218 (9.7) | 251 (10.1) | |
| >2 | 9 (3.7) | 65 (2.9) | 74 (3.0) | |
| Overall survival | ||||
| Alive | 161 (69.7) | 1884 (82.6) | 2045 (81.4) | |
| Dead | 70 (30.3) | 396 (17.4) | 466 (18.6) | |
| Mean follow-up (years, range) | 13.4 (0–23) | 13.4 (0–25) | 13.4 (0–25) | |
ED, erectile dysfunction; No ED, no erectile dysfunction; BMI, body-mass index; EPE, extra-prostatic extension; OC, organ confined; SVI, seminal vesicle involvement; LN, lymph nodes, RRP, radical retropubic prostatectomy.